Shih-chu Kao
Senior Scientist
management Team
Benitec Biopharma
Australia
Biography
Shih-Chu Kao is a Cellular and Molecular Biologist. She joined Benitec as a Senior Scientist in May 2014 and was one of the first two scientists who started the wet lab in Hayward, California. She is the lead scientist for Benitec’s Ocular Programs including Age-related Macular Degeneration. Shih-Chu acquired her first experience in developing ddRNAi-based therapy during her postdoc at Harvard Medical School studying Alzheimer’s disease. She was recruited to Tacere Therapeutics in 2008 and was one of the key scientists who developed TTO33X, series of compounds targeting Hepatitis C virus. During a brief break between Tacere and Benitec, Shih-Chu was the leader of the target validation group at Quanticel Pharmaceuticals, a small molecule drug company acquired by Celgene, developing epigenetic drugs targeting cancer stem cells. Shih-Chu holds a B.S. in Zoology from the National Taiwan University and earned her Ph.D. in Neurosciences at the Case Western Reserve University. She conducted her Postdoctoral studies in Howard Hughes Medical Institute sponsored laboratories at Harvard Medical School and Stanford University.
Research Interest
Research interest on Business development
